Clinical Trial Update: Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating imatinib (Glivec) in prostate cancer patients with rising PSA after radical prostatectomy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Glivec (imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostatic Neoplasm, Genital Neoplasms, Male | Phase 2 | Status: COMPLETED